BridgeBio Pharma Inc Total Assets
BridgeBio Pharma Inc total assets. Based on the latest financial reports, BridgeBio Pharma Inc (BBIO) holds total assets worth $1.22 Billion USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see BBIO market cap for the company's overall valuation and market capitalisation.
Total Assets of BridgeBio Pharma Inc (2017–2025)
Total assets of BridgeBio Pharma Inc from 2017 to 2025. This chart illustrates how BridgeBio Pharma Inc's total assets have evolved over time, based on quarterly financial data. See BridgeBio Pharma Inc share price for real-time trading data and today's change.
BridgeBio Pharma Inc - Asset Composition Analysis
BridgeBio Pharma Inc Total Assets Breakdown (December 2025)
BridgeBio Pharma Inc total assets breakdown as of December 2025. BridgeBio Pharma Inc's total assets of $1.22 Billion consist of 80.5% current assets and 19.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 60.9% |
| Accounts Receivable | $139.44 Million | 14.9% |
| Inventory | $26.75 Million | 2.9% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $28.08 Million | 3.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2017–2025)
This chart illustrates how BridgeBio Pharma Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore BBIO current assets to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: BridgeBio Pharma Inc's current assets represent 80.5% of total assets in 2025, a decrease from 99.1% in 2017.
- Cash Position: Cash and equivalents constituted 60.9% of total assets in 2025, down from 93.8% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, an increase from 0.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 14.9% of total assets.
BridgeBio Pharma Inc Competitors by Total Assets
Key competitors of BridgeBio Pharma Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
BridgeBio Pharma Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.23 | 5.19 | 6.68 |
| Quick Ratio | 1.17 | 5.08 | 6.68 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $202.49 Million | $736.42 Million | $543.89 Million |
BridgeBio Pharma Inc - Advanced Valuation Insights
This section examines the relationship between BridgeBio Pharma Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 123.68 |
| Latest Market Cap to Assets Ratio | 13.58 |
| Asset Growth Rate (YoY) | 1.8% |
| Total Assets | $936.02 Million |
| Market Capitalization | $12.71 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values BridgeBio Pharma Inc's assets at a significant premium (13.58x), suggesting investors see substantial growth potential or unique competitive advantages.
Positive Asset Growth: BridgeBio Pharma Inc's assets grew by 1.8% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for BridgeBio Pharma Inc (2017–2025)
The table below shows the annual total assets of BridgeBio Pharma Inc from 2017 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $936.02 Million | +1.82% |
| 2024-12-31 | $919.34 Million | +68.26% |
| 2023-12-31 | $546.38 Million | -12.30% |
| 2022-12-31 | $623.04 Million | -38.48% |
| 2021-12-31 | $1.01 Billion | +43.95% |
| 2020-12-31 | $703.59 Million | +11.38% |
| 2019-12-31 | $631.68 Million | +35.86% |
| 2018-12-31 | $464.94 Million | +374.22% |
| 2017-12-31 | $98.04 Million | -- |
About BridgeBio Pharma Inc
BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopteri… Read more